Related Experiment Videos

Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired

I Martin-Loeches1, T Lisboa, A Rodriguez

  • 1Critical Care Department, Mater Misericordiae University Hospital, Dublin, Ireland.

Intensive Care Medicine
|December 3, 2009
PubMed
Abstract

Insights

Macrolide use in intubated patients with severe community-acquired pneumonia (severe CAP) was associated with lower intensive care unit (ICU) mortality compared to fluoroquinolones. Combination therapy with macrolides is recommended for severe CAP patients.

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Severe community-acquired pneumonia (severe CAP) is a significant cause of mortality in intensive care units (ICUs).
  • Optimal antibiotic selection for intubated patients with severe CAP remains a critical clinical question.

Purpose of the Study:

  • To evaluate the comparative survival impact of macrolides versus fluoroquinolones in mechanically ventilated patients diagnosed with severe CAP.
  • To assess adherence to established clinical guidelines for empirical antibiotic therapy in this patient population.

Main Methods:

  • A prospective, observational, multicenter cohort study involving 218 intubated patients with severe CAP across 27 European ICUs.
  • Utilized Cox regression analysis to adjust for patient severity and compare mortality rates between macrolide and fluoroquinolone treatment groups.

Main Results:

  • ICU mortality was 37.6%. Macrolide use was significantly associated with reduced ICU mortality (HR 0.48) compared to fluoroquinolones, even in patients with severe sepsis or septic shock.
  • Empirical antibiotic therapy aligned with 2007 Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) guidelines in only 45.9% of cases.

Conclusions:

  • Adherence to 2007 IDSA/ATS guidelines for severe CAP management was suboptimal.
  • Combination therapy incorporating macrolides should be prioritized for intubated patients with severe CAP to improve survival outcomes.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...